Search results for "Hdl"

showing 10 items of 298 documents

Prevalence of ANGPTL3 and APOB gene mutations in subjects with combined hypolipidemia.

2012

Objective— Mutations of the ANGPTL3 gene have been associated with a novel form of primary hypobetalipoproteinemia, the combined hypolipidemia (cHLP), characterized by low total cholesterol and low HDL-cholesterol levels. The aim of this work is to define the role of ANGPTL3 gene as determinant of the combined hypolipidemia phenotype in 2 large cohorts of 913 among American and Italian subjects with primary hypobetalipoproteinemia (total cholesterol <5th percentile). Methods and Results— The combined hypolipidemia cut-offs were chosen according to total cholesterol and HDL-cholesterol levels reported in the ANGPTL3 kindred described to date: total cholesterol levels, <2nd percentile …

MaleSettore MED/09 - Medicina InternaApolipoprotein BGene mutationCompound heterozygositymedicine.disease_causeSeverity of Illness IndexHypobetalipoproteinemiaschemistry.chemical_compoundGene Frequency80 and overPrevalenceMissense mutationgeneticsepidemiology; genetics; hypobetalipoproteinemia; lipoproteins; Adolescent; Adult; Aged; Aged 80 and over; Amino Acid Sequence; Angiopoietins; Apolipoproteins B; Biomarkers; Cholesterol; Cholesterol HDL; Female; Gene Frequency; Genetic Predisposition to Disease; Heterozygote; Homozygote; Humans; Hypobetalipoproteinemias; Italy; Male; Middle Aged; Missouri; Molecular Sequence Data; Phenotype; Prevalence; Severity of Illness Index; Young Adult; Codon Nonsense; Mutation Missense; Cardiology and Cardiovascular MedicineAged 80 and overMutationHomozygotehypobetalipoproteinemiaMiddle AgedCholesterolPhenotypeItalyCodon NonsenseepidemiologyFemaleCardiology and Cardiovascular MedicineHumanAdultmedicine.medical_specialtyHeterozygoteHDLAdolescentMolecular Sequence DataMutation MissenseSocio-culturaleAngiopoietinepidemiology; lipoproteins; genetics; hypobetalipoproteinemiaBiologyYoung AdultInternal medicinemedicineHumansGenetic Predisposition to DiseaseAmino Acid SequenceCodonAllele frequencyAgedAngiopoietin-Like Protein 3Apolipoproteins BMissouriCholesterolCholesterol HDLmedicine.diseaselipoproteinsEndocrinologyAngiopoietin-like ProteinsNonsensechemistryBiological MarkerMutationbiology.proteinHypobetalipoproteinemiaMissenseAngiopoietinsBiomarkersArteriosclerosis, thrombosis, and vascular biology
researchProduct

Enhanced lipid peroxidation and platelet activation as potential contributors to increased cardiovascular risk in the low-HDL phenotype

2013

Background Low high‐density lipoprotein ( HDL ) levels are major predictors of cardiovascular ( CV ) events, even in patients on statin treatment with low‐density lipoprotein ( LDL ) at target. In animal models HDL s protect LDL from oxidation and blunt platelet activation. Our study aimed to examine whether HDL levels are related to in vivo oxidative stress and platelet activation, as determinants of atherothrombosis. Methods and Results Urinary 8‐iso‐PGF 2α and 11‐dehydro‐TXB 2 , in vivo markers of oxidative stress and platelet activation, respectively, were measured in 65 coronary heart disease (CHD) normocholesterolemic patients with HDL ≤35 mg/ dL , and in 47 CHD patients with HDL &gt…

MaleSettore MED/09 - Medicina InternaCoronary DiseaseDinoprostmedicine.disease_causeLipid peroxidationchemistry.chemical_compoundFenofibrateHDL cholesterolRisk FactorsCoronary Heart Diseaseoxidative stressMyocardial infarctionOriginal ResearchHypolipidemic AgentsplateletHypoalphalipoproteinemiasFenofibrateMiddle AgedAged; Arachidonic Acids; Case-Control Studies; Cholesterol HDL; Coronary Disease; Cross-Sectional Studies; Dinoprost; Exercise; Exercise Therapy; Female; Fenofibrate; Humans; Hypoalphalipoproteinemias; Hypolipidemic Agents; Lipid Peroxidation; Male; Middle Aged; Oxidative Stress; Phenotype; Platelet Activation; Risk Factors; Sedentary Lifestyle; Thromboxane B2; Cardiology and Cardiovascular MedicineExercise TherapyCholesterolPhenotypeSedentary LifestyleFemalelipids (amino acids peptides and proteins)exercise HDL cholesterol oxidative stress plateletCardiology and Cardiovascular Medicinemedicine.drugmedicine.medical_specialtyHDLArachidonic AcidsDiabetes mellitusInternal medicinemedicineHumansPlatelet activationExerciseAgedCreatininebusiness.industryCholesterol HDLCase-control studyPlatelet Activationmedicine.diseaseThromboxane B2Cross-Sectional StudiesEndocrinologychemistryCase-Control StudiesLipid PeroxidationSedentary BehaviorbusinessOxidative stressLipoproteinEuropean Heart Journal
researchProduct

Remarkable quantitative and qualitative differences in HDL after niacin or fenofibrate therapy in type 2 diabetic patients

2014

Abstract HDL-increasing drugs such as fenofibrate and niacin have failed to decrease the cardiovascular risk in patients with type 2 diabetes. Drug-mediated quantitative and qualitative HDL modifications could be involved in these negative results. To evaluate the quantitative and qualitative effects of niacin and fenofibrate on HDL in patients with type 2 diabetes, a prospective, randomised controlled intervention trial was conducted. Thirty type 2 diabetic patients with low HDL were randomised to receive either fenofibrate (FFB) or niacin + laropiprant (ERN/LPR) as an add-on to simvastatin treatment for 12 weeks according to a crossover design. At the basal point and after each interventi…

MaleSimvastatinIndolesTime FactorsType 2 diabetesHigh-Density Lipoproteins Pre-betaAntioxidantsBasal (phylogenetics)chemistry.chemical_compoundFenofibrateProspective StudiesHypolipidemic AgentsFenofibrateMiddle AgedOxidantsPON1Up-RegulationTreatment OutcomeDrug Therapy CombinationFemalelipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicineNiacinmedicine.drugAdultmedicine.medical_specialtyNiacinbehavioral disciplines and activitiesInternal medicinemedicineHumansMetabolomicsParticle SizeAgedDyslipidemiasbusiness.industryCholesterolCholesterol HDLnutritional and metabolic diseasesmedicine.diseaseCrossover studyCross-Sectional StudiesEndocrinologyDiabetes Mellitus Type 2chemistrySpainSimvastatinHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessBiomarkersAtherosclerosis
researchProduct

Ezetimibe/simvastatin 10/20 mg versus simvastatin 40 mg in coronary heart disease patients

2010

BACKGROUND: Reducing low-density lipoprotein cholesterol (LDL-C) is the primary goal of therapy in patients with hypercholesterolemia and coronary heart disease (CHD). METHODS: This double blind placebo-controlled study enrolled patients 18 to 75 years of age with primary hypercholesterolemia and establishedCHDwhowere taking a stable daily dose of simvastatin 20 mg. Patients were randomized to ezetimibe/simvastatin 10/20 mg (eze/simva; n 5 56) or simvastatin 40 mg (simva; n 5 56) for 6 weeks. Percent change from baseline in LDL-C, total cholesterol, high-density lipoprotein cholesterol (HDL-C), and triglycerides were assessed by use of the Student t test. The percent of patients achieving L…

MaleSimvastatinSettore MED/09 - Medicina InternaEndocrinology Diabetes and MetabolismCoronary DiseasePharmacologyGastroenterologylaw.inventionchemistry.chemical_compoundRandomized controlled triallawCholesterol absorption inhibitorEzetimibe; simvastatin; coronary heart diseaseNutrition and DieteticsAnticholesteremic AgentsMiddle AgedLipidCoronary heart diseaseCholesterolDrug Therapy CombinationFemalelipids (amino acids peptides and proteins)Cardiology and Cardiovascular Medicinemedicine.drugAdultmedicine.medical_specialtyAdolescentmedicine.drug_classHypercholesterolemiaPharmacotherapyDouble-Blind MethodEzetimibeInternal medicineInternal MedicinemedicineHumansTriglyceridesCholesterol absorption inhibitorAgedCholesterolbusiness.industryCholesterol HDLCholesterol absorption inhibitor; Coronary heart disease; Ezetimibe; Lipids; SimvastatinCholesterol LDLEzetimibeClinical trialchemistrySimvastatinAzetidinesEzetimibe/simvastatinbusinessJournal of Clinical Lipidology
researchProduct

Effects of lipid-lowering drugs on high-density lipoprotein subclasses in healthy men-a randomized trial.

2013

Context and Objective Investigating the effects of lipid-lowering drugs on HDL subclasses has shown ambiguous results. This study assessed the effects of ezetimibe, simvastatin, and their combination on HDL subclass distribution. Design and Participants A single-center randomized parallel 3-group open-label study was performed in 72 healthy men free of cardiovascular disease with a baseline LDL-cholesterol of 111±30 mg/dl (2.9±0.8 mmol/l) and a baseline HDL-cholesterol of 64±15 mg/dl (1.7±0.4 mmol/l). They were treated with ezetimibe (10 mg/day, n = 24), simvastatin (40 mg/day, n = 24) or their combination (n = 24) for 14 days. Blood was drawn before and after the treatment period. HDL subc…

MaleSimvastatinlcsh:MedicinePharmacologyBiochemistryLipoprotein MetabolismVascular MedicineSubclasslaw.inventionchemistry.chemical_compoundHigh-density lipoproteinRandomized controlled triallawMedicine and Health SciencesMedicinelcsh:ScienceHypolipidemic AgentsMultidisciplinaryHealthy VolunteersResearch DesignDrug Therapy Combinationlipids (amino acids peptides and proteins)Lipoproteins HDLResearch Articlemedicine.drugAdultmedicine.medical_specialtylipid-lowering drugs high-density lipoprotein healthy menDrug Research and DevelopmentClinical Research DesignLipoproteinsHypercholesterolemiaCardiologyAdipokineContext (language use)Research and Analysis MethodsCardiovascular PharmacologyAdipokinesEzetimibeInternal medicineHumansClinical TrialsPharmacologybusiness.industryCholesterollcsh:RBiology and Life SciencesProteinsnutritional and metabolic diseasesEzetimibeAtherosclerosisGlucoseEndocrinologychemistrySimvastatinAzetidineslcsh:QClinical MedicinebusinessBiomarkersPLoS ONE
researchProduct

Switching from statin monotherapy to ezetimibe/simvastatin or rosuvastatin modifies the relationships between apolipoprotein B, LDL cholesterol, and …

2011

OBJECTIVE: To evaluate relationships between apolipoprotein B (Apo B), LDL cholesterol (LDL-C), and non-HDL-C in high-risk patients treated with lipid-lowering therapy. DESIGN AND METHODS: This post-hoc analysis calculated LDL-C and non-HDL-C levels corresponding to an Apo B of 0.9 g/L following treatment with 1) statin monotherapy (baseline) and 2) ezetimibe/simvastatin 10/20mg or rosuvastatin 10mg (study end). The percentages of patients reaching LDL-C, non-HDL-C, and Apo B targets were calculated at study end. RESULTS: After switching to ezetimibe/simvastatin or rosuvastatin, the LDL-C and non-HDL-C corresponding to Apo B=0.9 g/L were closer to the more aggressive LDL-C and non-HDL-C goa…

MaleSimvastatinmedicine.medical_specialtySettore MED/09 - Medicina InternaStatinApolipoprotein Bmedicine.drug_classHypercholesterolemiaClinical BiochemistryCoronary DiseaseGastroenterologyRosuvastatinEzetimibeEzetimibe/simvastatin; Rosuvastatin; Correlation; Apolipoprotein B; Low-density lipoprotein cholesterol; Non-high-density lipoprotein cholesterolInternal medicinemedicineHumansLow-density lipoprotein cholesterolRosuvastatinRosuvastatin CalciumAgedApolipoproteins BLdl cholesterolSulfonamidesbiologyEzetimibe/simvastatinbusiness.industrynutritional and metabolic diseasesGeneral MedicineMiddle AgedEzetimibeCorrelationFluorobenzenesNon-high-density lipoprotein cholesterolCholesterolPyrimidinesSimvastatinNon hdl cholesterolbiology.proteinAzetidinesFemalelipids (amino acids peptides and proteins)Ezetimibe/simvastatinHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessApolipoprotein Bmedicine.drugClinical Biochemistry
researchProduct

Associations between serum uric acid concentrations and metabolic syndrome and its components in the PREDIMED study.

2015

Several studies have demonstrated a relationship between increased serum uric acid (SUA) concentrations and the prevalence of metabolic syndrome (MetS) in the oriental population. However, to the best of our knowledge, the association between SUA and MetS has never been investigated in elderly European individuals at high cardiovascular risk. The aim of this study was to conduct a cross-sectional and prospective evaluation of the associations between SUA concentrations and the MetS in elderly individuals at high cardiovascular risk.Men and women (55-80 years of age) from different PREDIMED (Prevención con DIeta MEDiterránea) recruiting centers were studied. Baseline cross-sectional (n = 441…

MaleSíndrome metabòlicamedicine.medical_specialtyCross-sectional studyEndocrinology Diabetes and MetabolismPopulationMedicine (miscellaneous)0939-4753HyperuricemiaBioquímica i biotecnologiaBody Mass IndexAsian PeopleRisk FactorsInternal medicineSurveys and QuestionnairesPrevalenceMedicineHumansHyperuricemiaProspective StudieseducationProspective cohort studyAgedAged 80 and overHypertriglyceridemiaMetabolic SyndromeBioquímica y tecnologíaeducation.field_of_studyNutrition and Dieteticsbusiness.industryHazard ratioCholesterol HDLPREDIMED studyCholesterol LDLMiddle Agedmedicine.diseaseUric AcidBiochemistry and technologyCross-Sectional StudiesLogistic ModelsQuartileCardiovascular DiseasesHypertensionFemaleMetabolic syndromeCardiology and Cardiovascular MedicinebusinessBody mass indexFollow-Up StudiesNutrition, metabolism, and cardiovascular diseases : NMCD
researchProduct

Fenofibrate effect on triglyceride and postprandial response of apolipoprotein A5 variants: the GOLDN study.

2007

Objective— Apolipoprotein A5 ( APOA5 ) is a key determinant of plasma triglyceride (TG) concentrations. Genetic variation at the APOA5 locus could be responsible for some of the observed differences in response to fenofibrate therapy. Methods and Results— We examined the association between tag SNPs (−1131T>C and 56C>G) at APOA5 and TG and HDL-C response to fenofibrate and a postprandial lipid challenge in 791 men and women participating in the GOLDN study. After 3-week drug treatment, APOA5 56G carriers displayed significant decrease in TG ( P =0.006), and increase in HDL-C ( P =0.002) levels relative to their basal values in the fasting state when compared with noncarriers (a TG re…

MaleTime FactorsApolipoprotein BAdministration Oralchemistry.chemical_compoundFenofibrateGene FrequencyApolipoprotein a5Hypolipidemic AgentsAged 80 and overFenofibratebiologyMiddle AgedPostprandial PeriodPostprandialTreatment OutcomeArea Under CurveFemaleCardiology and Cardiovascular Medicinemedicine.drugAdultmedicine.medical_specialtyGuanineAdolescentGenotypeSingle-nucleotide polymorphismHyperlipidemiasPolymorphism Single NucleotideCytosineInternal medicinemedicineHumansParticle SizeApolipoproteins ATriglyceridesAgedTriglyceridebusiness.industryCholesterolCholesterol HDLCholesterol LDLDrug interactionLipid MetabolismDietary FatsUnited StatesEndocrinologychemistryApolipoprotein A-Vbiology.proteinbusinessThymineArteriosclerosis, thrombosis, and vascular biology
researchProduct

TRIB1 constitutes a molecular link between regulation of sleep and lipid metabolism in humans.

2012

Epidemiological studies show association between sleep duration and lipid metabolism. In addition, inactivation of circadian genes induces insulin resistance and hyperlipidemia. We hypothesized that sleep length and lipid metabolism are partially controlled by the same genes. We studied the association of total sleep time (TST) with 60 genetic variants that had previously been associated with lipids. The analyses were performed in a Finnish population-based sample (N = 6334) and replicated in 2189 twins. Finally, RNA expression from mononuclear leucocytes was measured in 10 healthy volunteers before and after sleep restriction. The genetic analysis identified two variants near TRIB1 gene th…

MaleTwinsBlood lipidsGene ExpressionCohort Studies0302 clinical medicineGene FrequencySleep and metabolismHomeostasisgeneticsta515FinlandSlow-wave sleepSleep restriction2. Zero hunger0303 health sciencesIntracellular Signaling Peptides and Proteinsta3141Middle AgedSleep in non-human animals3142 Public health care science environmental and occupational health3. Good healthPsychiatry and Mental healthFemaleOriginal Articleepidemiologymedicine.symptomAdultmedicine.medical_specialtyGenotypeSNPDisorders of Excessive SomnolenceBiologyProtein Serine-Threonine Kinasesta3111Polymorphism Single Nucleotidelipids03 medical and health sciencesCellular and Molecular NeuroscienceInternal medicinemedicineHumansCircadian rhythmsleepBiological PsychiatryAllelesGenetic Association StudiesTriglycerides030304 developmental biologyAgedCholesterol HDLGenetic VariationLipid metabolismCholesterol LDLLipid Metabolismta3124Sleep deprivationEndocrinologySleep Deprivationmetabolism030217 neurology & neurosurgeryTranslational psychiatry
researchProduct

Changes in Serum and Lipoprotein Fatty Acids of Growing Rats Fed Protein-Deficient Diets with Low or Adequate Linolenic Acid Concentrations

1992

The effects of a protein-deficient diet associated with sunflower oil [adequate in 18:2(n-6), poor in 18:3(n-3)] or soybean oil [adequate in both 18:2(n-6) and 18:3(n-3)] on lipid serum and lipoprotein compositions were studied in growing rats. Four groups of rats were fed different diets: SFC (20% casein + 5% sunflower oil); SFd (2% casein + 5% sunflower oil); SC (20% casein + 5% soybean oil); Sd (2% casein + 5% soybean oil). After 28 d, both protein-deficient groups exhibited low concentrations of protein, phospholipid, triacylglycerol and total cholesterol in serum and VLDL. Compared with rats fed 20% casein diets, those fed low protein diets had lower 18:2(n-6) and 20:4(n-6) in phosphol…

MaleVery low-density lipoproteinmedicine.medical_specialtyfood.ingredientLow proteinLinolenic AcidsLinolenic acidLipoproteinsMedicine (miscellaneous)Lipoproteins VLDLBiologySoybean oilfoodProtein DeficiencyInternal medicineCaseinmedicineAnimalsFood sciencePhospholipidsTriglycerideschemistry.chemical_classificationNutrition and DieteticsSunflower oilFatty AcidsFatty acidRats Inbred StrainsRatsEndocrinologychemistryHelianthuslipids (amino acids peptides and proteins)SoybeansLipoproteins HDLPolyunsaturated fatty acidThe Journal of Nutrition
researchProduct